Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294)
China
· Delayed Price · Currency is CNY 30.93
-0.25 (-0.80%)
Nov 15, 2024, 3:04 PM CST
Shenzhen Salubris Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 3,824 | 3,280 | 3,401 | 3,020 | 2,731 | 4,459 | Upgrade
|
| Other Revenue | 85.67 | 85.67 | 81.27 | 38.73 | 7.07 | 10.98 | Upgrade
|
| Revenue | 3,910 | 3,365 | 3,482 | 3,058 | 2,739 | 4,470 | Upgrade
|
| Revenue Growth (YoY) | 15.34% | -3.35% | 13.85% | 11.68% | -38.74% | -3.90% | Upgrade
|
| Cost of Revenue | 1,119 | 1,065 | 1,001 | 811.29 | 847.87 | 964.55 | Upgrade
|
| Gross Profit | 2,791 | 2,300 | 2,481 | 2,247 | 1,891 | 3,506 | Upgrade
|
| Selling, General & Admin | 1,674 | 1,302 | 1,332 | 1,340 | 1,187 | 1,855 | Upgrade
|
| Research & Development | 459.4 | 409.19 | 533.75 | 357.37 | 371.2 | 763.5 | Upgrade
|
| Other Operating Expenses | 64.6 | 43.56 | 46.93 | 44.98 | 34.67 | 63.24 | Upgrade
|
| Operating Expenses | 2,197 | 1,757 | 1,916 | 1,743 | 1,584 | 2,681 | Upgrade
|
| Operating Income | 593.96 | 542.47 | 565.58 | 504.3 | 306.3 | 824.45 | Upgrade
|
| Interest Expense | -15.7 | -17.37 | -12.54 | -10.53 | -17.57 | -16.01 | Upgrade
|
| Interest & Investment Income | 75.07 | 80.94 | 151.26 | 181.9 | 35.5 | 16.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.01 | 3.01 | 5.55 | -5.78 | -5.35 | 1.54 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.6 | -0.43 | -5.84 | -7.54 | -21.46 | 1.81 | Upgrade
|
| EBT Excluding Unusual Items | 644.74 | 608.61 | 704 | 662.35 | 297.43 | 827.84 | Upgrade
|
| Impairment of Goodwill | -49.61 | -49.61 | -26.61 | - | -282.72 | -10.99 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.48 | 8.09 | 3.81 | - | -26.78 | -31.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.18 | -0.48 | -0.18 | -1.3 | 0.21 | -1.11 | Upgrade
|
| Asset Writedown | -14.87 | -1.03 | -24.06 | -131.6 | -1.59 | -1.61 | Upgrade
|
| Other Unusual Items | 76.18 | 76.18 | 56.76 | 70.39 | 70.21 | 68.42 | Upgrade
|
| Pretax Income | 666.09 | 641.76 | 713.73 | 599.84 | 56.74 | 851.35 | Upgrade
|
| Income Tax Expense | 50.36 | 60.93 | 79.36 | 71.52 | 6.61 | 169.51 | Upgrade
|
| Earnings From Continuing Operations | 615.72 | 580.83 | 634.37 | 528.32 | 50.13 | 681.84 | Upgrade
|
| Minority Interest in Earnings | -5.12 | -0.76 | 2.73 | 5.41 | 10.73 | 33.36 | Upgrade
|
| Net Income | 610.61 | 580.07 | 637.09 | 533.73 | 60.86 | 715.2 | Upgrade
|
| Net Income to Common | 610.61 | 580.07 | 637.09 | 533.73 | 60.86 | 715.2 | Upgrade
|
| Net Income Growth | 5.89% | -8.95% | 19.37% | 776.90% | -91.49% | -50.95% | Upgrade
|
| Shares Outstanding (Basic) | 1,111 | 1,116 | 1,098 | 1,067 | 1,014 | 1,052 | Upgrade
|
| Shares Outstanding (Diluted) | 1,111 | 1,116 | 1,098 | 1,067 | 1,014 | 1,052 | Upgrade
|
| Shares Change (YoY) | 0.23% | 1.55% | 2.90% | 5.23% | -3.55% | 0.26% | Upgrade
|
| EPS (Basic) | 0.55 | 0.52 | 0.58 | 0.50 | 0.06 | 0.68 | Upgrade
|
| EPS (Diluted) | 0.55 | 0.52 | 0.58 | 0.50 | 0.06 | 0.68 | Upgrade
|
| EPS Growth | 5.65% | -10.34% | 16.00% | 733.33% | -91.18% | -51.08% | Upgrade
|
| Free Cash Flow | 561.22 | 168.44 | 371.84 | 702.48 | 731.86 | 1,049 | Upgrade
|
| Free Cash Flow Per Share | 0.51 | 0.15 | 0.34 | 0.66 | 0.72 | 1.00 | Upgrade
|
| Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.400 | - | 0.500 | Upgrade
|
| Dividend Growth | 0% | 0% | 25.00% | - | - | -37.50% | Upgrade
|
| Gross Margin | 71.37% | 68.34% | 71.26% | 73.47% | 69.04% | 78.42% | Upgrade
|
| Operating Margin | 15.19% | 16.12% | 16.24% | 16.49% | 11.18% | 18.44% | Upgrade
|
| Profit Margin | 15.62% | 17.24% | 18.30% | 17.45% | 2.22% | 16.00% | Upgrade
|
| Free Cash Flow Margin | 14.35% | 5.01% | 10.68% | 22.97% | 26.72% | 23.48% | Upgrade
|
| EBITDA | 937.49 | 870.81 | 873.67 | 798.4 | 552.33 | 1,054 | Upgrade
|
| EBITDA Margin | 23.98% | 25.88% | 25.09% | 26.11% | 20.17% | 23.57% | Upgrade
|
| D&A For EBITDA | 343.53 | 328.34 | 308.09 | 294.1 | 246.03 | 229.36 | Upgrade
|
| EBIT | 593.96 | 542.47 | 565.58 | 504.3 | 306.3 | 824.45 | Upgrade
|
| EBIT Margin | 15.19% | 16.12% | 16.24% | 16.49% | 11.18% | 18.44% | Upgrade
|
| Effective Tax Rate | 7.56% | 9.49% | 11.12% | 11.92% | 11.65% | 19.91% | Upgrade
|
| Revenue as Reported | 3,910 | 3,365 | 3,482 | 3,058 | 2,739 | 4,470 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.